Sardar Biglari Sells 11,000 Shares of VanEck Biotech ETF (NASDAQ:BBH) Stock

Posted by Jeff Wilder on Jul 23rd, 2026

VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) major shareholder Sardar Biglari sold 11,000 shares of VanEck Biotech ETF stock in a transaction dated Friday, July 17th. The stock was sold at an average price of $16.71, for a total transaction of $183,810.00. Following the completion of the transaction, the insider owned 3,538,961 shares of the company’s stock, valued at $59,136,038.31. The trade was a 0.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Sardar Biglari also recently made the following trade(s):

On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.70, for a total transaction of $45,908.30.
On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.71, for a total value of $109,166.43.
On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.73, for a total value of $20,260.03.

VanEck Biotech ETF Trading Down 1.1%

Shares of NASDAQ BBH opened at $201.15 on Thursday. The stock has a fifty day moving average of $193.99 and a 200-day moving average of $192.22. VanEck Biotech ETF has a fifty-two week low of $156.45 and a fifty-two week high of $212.54.

Institutional Trading of VanEck Biotech ETF

Several institutional investors and hedge funds have recently bought and sold shares of the company. Empowered Funds LLC purchased a new stake in shares of VanEck Biotech ETF in the 4th quarter valued at about $38,000. Flagship Harbor Advisors LLC purchased a new stake in VanEck Biotech ETF in the fourth quarter valued at approximately $47,000. Allworth Financial LP lifted its position in VanEck Biotech ETF by 255.0% during the fourth quarter. Allworth Financial LP now owns 426 shares of the company’s stock valued at $81,000 after purchasing an additional 306 shares during the last quarter. Fifth Third Bancorp purchased a new stake in shares of VanEck Biotech ETF during the 1st quarter valued at $127,000. Finally, Huntington National Bank purchased a new stake in shares of VanEck Biotech ETF during the 4th quarter valued at $132,000. 32.05% of the stock is currently owned by hedge funds and other institutional investors.

About VanEck Biotech ETF

(Get Free Report)

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.